Universal Health Services, Inc. (UHS) Q3 2024 Earnings Call Transcript Summary
Universal Health Services, Inc. (UHS) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Universal Health Services, Inc. (UHS) Q3 2024 Earnings Call Transcript:
以下是Universal Health Services, Inc.（UHS）2024年第三季度业绩会议呼叫记录摘要：
Financial Performance:
金融业绩：
UHS reported adjusted net income per diluted share of $3.71 for Q3 2024.
Revenue growth for the quarter was solid at 8.6%, excluding impacts from the insurance subsidiary.
EBITDA at acute care hospitals increased substantially by 36% compared to the prior year quarter on the same facility basis.
UHS报告2024年第三季度调整后每股稀释净利润为3.71美元。
本季度营业收入增长稳健，达到8.6%，不包括保险子公司的影响。
急性护理医院的EBITDA按同一设施基础上较上一年同期大幅增长36%。
Business Progress:
业务进展：
Acute care volumes have moderated but are returning to pre-pandemic patterns.
Opened the 128 bed Riva Vista Behavioral Health Hospital and progressing with construction of other facilities.
Continuous development in both acute and behavioral health segments, including joint ventures and capacity expansions.
急性护理病例数量有所稳定，但正在恢复至疫情前的模式。
开设了拥有128张床位的Riva Vista心理健康医院，并正在推进其他医疗设施的施工。
在急性和行为健康领域不断发展，包括合资经营和扩 capacity。
Opportunities:
机会：
Medicaid supplemental payment programs, especially new approvals in Tennessee and Washington, D.C., could lead to substantial financial benefits.
Expansion and development in both inpatient and ambulatory care facilities.
医疗补充付款计划，特别是在田纳西州和华盛顿特区的新批准，可能带来可观的财务利益。
在住院和门诊护理设施的扩建和发展。
Risks:
风险：
Increase in reserves for self-insured claims indicates potential issues in liability management.
Aggressive behavior from managed care payers, with no significant change noted in the current quarter.
为自保索赔提高储备表明责任管理可能存在潜在问题。
托管付款机构的激进行为，当前季度未见显著变化。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章内容的准确性无法完全保证。有关更全面的详细信息，请参阅IR网站。本文只是为投资者提供参考，没有任何指导或推荐建议。
